Italia markets closed

Abeona Therapeutics Inc. (0H7R.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
4,0650-0,0230 (-0,56%)
Alla chiusura: 05:59PM BST
Schermo intero
Chiusura precedente4,0880
Aperto4,1000
Denaro0,0000 x N/D
Domanda0,0000 x N/D
Min-Max giorno4,0200 - 4,1000
Intervallo di 52 settimane2,3501 - 8,8000
Volume4.245
Media Volume1.007
Capitalizzazione1,136M
Beta (mensile su 5 anni)1,58
Rapporto PE (ttm)N/D
EPS (ttm)-0,8080
Prossima data utili06 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

    CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). As part of the submission, Abeona requested a Priority Review, which, if granted, would shorten the FDA’s review perio

  • GlobeNewswire

    Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer

    CLEVELAND, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer (CCO) and Head of Business Development (BD), effective immediately. In this capacity, in addition to his current BD responsibilities, Dr. Vasanthavada will oversee all aspects of commercial strategy, planning and operations as Abeona prepares for a potential launch of EB-101, its investigational, geneti

  • GlobeNewswire

    Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

    CLEVELAND, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2023: A company presentation at the H.C. Wainwright Annual Global Investment Conference on Wednesday, September 13, 2023 at 10:00 a.m. ET.A fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 2:10 p.m. ET.A fireside chat at the Jefferies Cell & Genetic Medicin